Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Dabrafenib in combination with Trametinib in patients with Melanoma.

Statements

Source and description
Tafinlar (dabrafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Tafinlar (dabrafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
Mekinist (trametinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Mekinist (trametinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.